Abstract Types

CRA
Clinical Review Abstract

LBA
Late-Breaking Abstract

TPS
Trials in Progress Abstract

e
Abstracts selected for publication but not presentation at the Annual Meeting

^
Abstracts granted an exception in accordance with ASCO's Conflict of Interest Policy



RTOG 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients.

Sub-category:
Local-regional Non-small Cell Lung Cancer

Category:
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

Meeting:
2013 ASCO Annual Meeting

Abstract No:
7523

Citation:
J Clin Oncol 31, 2013 (suppl; abstr 7523)

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2013 Annual Meeting but not presented at the Meeting, can be found online only.

Author(s): Robert D. Timmerman, Rebecca Paulus, Harvey I. Pass, Elizabeth Gore, Martin J. Edelman, James M. Galvin, Hak Choy, William Straube, Lucien Alexander Nedzi, Ronald McGarry, Cliff Grant Robinson, Peter B. Schiff, Jeffrey D. Bradley; The University of Texas Southwestern Medical Center, Dallas, TX; Radiation Therapy Oncology Group, Statistical Center, Philadelphia, PA; New York University School of Medicine, New York, NY; Medical College of Wisconsin, Milwaukee, WI; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; Thomas Jefferson University Hospital, Philadelphia, PA; Washington University in St. Louis, St. Louis, MO; University of Kentucky, Lexington, KY

Abstract Disclosures


Abstract:

Background: The Radiation Therapy Oncology Group (RTOG) protocol 0618 was a phase II trial utilizing SBRT to treat early stage non-small cell lung cancer in operable patients (pts). Methods: All pts were deemed operable by a thoracic surgeon utilizing specific criteria. Pts with biopsy proven peripheral T1-T3, N0, M0 tumors were eligible. The prescription dose was 18 Gy X 3 fractions delivered in 1½-2 weeks. The primary endpoint was 2-year primary tumor control (PTC, avoidance of in-field (INF) and marginal failure (MF)) with overall and progression free survival (OS, PFS), adverse events (AE), local (LF), regional (RF), and distant failure (DF) as secondary endpoints. Early surgical salvage was directed as part of protocol design in the event of LF after SBRT. Results: The study opened December 2007 and closed May 2010 after accruing a total of 33 pts. Of 26 evaluable pts, 23 had T1, and 3 had T2 tumors. Median age was 72 years. Median FEV1, DLCO at enrollment were 72%, 68% predicted, respectively. 4 pts (16%) had SBRT related grade 3 AEs while 0 had grade 4-5 AEs. Median follow-up was 25 months. 2 pts have been scored with INF (11.7 and 12.4 months post SBRT) and 1 with MF (32.5 months post SBRT) giving an estimated 2-year primary tumor failure rate of 7.7% (95% CI: 0.0%, 18.1%). 2-year estimates of LF (primary tumor plus involved lobe failure), RF, and DF are 19.2% (95% CI: 3.7%, 34.7%), 11.7% (95% CI: 0.0%, 24.5%), and 15.4% (95% CI: 1.2%, 29.6%), respectively. Only one patient was eligible for attempted surgical salvage and underwent lobectomy 1.2 years post SBRT complicated by a grade 4 cardiac arrhythmia. 2-year estimates of PFS and OS are 65.4% (95% CI: 44.0%, 80.3%) and 84.4% (95% CI: 63.7%, 93.9%), respectively. Conclusions: SBRT given appears to be associated with a high rate of PTC, moderate treatment related morbidity, and infrequent need for surgical salvage in operable early stage lung cancer pts with peripheral lesions. These results support ongoing enrollment into the ACOSOG Z4099-RTOG 1021 trial comparing SBRT to sublobar resection in high risk operable pts. The project was supported by RTOG grant U10 CA21661, CCOP grant U10 CA37422, and ATC U24 CA81647 from the National Cancer Institute. Clinical trial information: NCT00551369.

 

  Other Abstracts in this Sub-Category:

 

1. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

Meeting: 2013 ASCO Annual Meeting Abstract No: 7500 First Author: C. A. Butts
Category: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers - Local-regional Non-small Cell Lung Cancer

 

2. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.

Meeting: 2013 ASCO Annual Meeting Abstract No: 7501 First Author: J. D. Bradley
Category: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers - Local-regional Non-small Cell Lung Cancer

 

3. Impact of brachytherapy on local recurrence after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer (NSCLC).

Meeting: 2013 ASCO Annual Meeting Abstract No: 7502 First Author: H. C. Fernando
Category: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers - Local-regional Non-small Cell Lung Cancer

 

More...